2017
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset
Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Research And Treatment 2017, 162: 1-10. PMID: 28064383, PMCID: PMC5909985, DOI: 10.1007/s10549-016-4093-4.Peer-Reviewed Original ResearchConceptsIntermediate-risk diseaseOncotype DX recurrence scoreHigh-risk diseaseDX recurrence scoreODX RSReceptor statusRecurrence scoreSurrogate markerProgesterone receptor statusInvasive breast cancerEstrogen receptor statusHigh-risk groupOngoing clinical trialsMagee EquationsPresence of patientsAdjuvant chemotherapyClinicopathologic dataRetrospective studyTumor sizeHER2 statusHistopathologic variablesClinical trialsBreast cancerPatient managementAdditional independent validation
2013
Risk of Acute Thromboembolic Events With Oral Contraceptive Use
Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, Sanders GD, Myers ER. Risk of Acute Thromboembolic Events With Oral Contraceptive Use. Obstetrics And Gynecology 2013, 122: 380-389. PMID: 23969809, DOI: 10.1097/aog.0b013e3182994c43.Peer-Reviewed Original ResearchConceptsOral contraceptive pillsVenous thromboembolismMyocardial infarctionIschemic strokeHemorrhagic strokeOdds ratioCombined oral contraceptive pillAcute thromboembolic eventsOral contraceptive useRandomized clinical trialsSummary odds ratiosThromboembolic eventsCochrane DatabaseContraceptive pillsOCP useOCP usersClinical trialsSTUDY SELECTIONInclusion criteriaContraceptive useThromboembolismDiscordant decisionsSystematic reviewStrokeTeam review
2012
Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial
DeWitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, Reed SD. Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial. Value In Health 2012, 15: 277-283. PMID: 22433759, DOI: 10.1016/j.jval.2011.11.027.Peer-Reviewed Original ResearchConceptsLung functionMild impairmentCystic fibrosisClinical trialsAeruginosa colonizationHealth Utilities Index Mark 2/3Study case report formsPrimary end pointNationwide Inpatient SampleDirect medical costsMulticenter clinical trialP. aeruginosa colonizationPseudomonas aeruginosa colonizationMean annual costCase report formsLong-term useUtility estimatesEmergency visitsHospital admissionDornase alfaMedication costsRandomized trialsMean ageFemale sexInpatient Sample
2011
Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials
Dinan MA, Compton KL, Dhillon JK, Hammill BG, DeWitt EM, Weinfurt KP, Schulman KA. Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials. Medical Care 2011, 49: 415-419. PMID: 21368680, PMCID: PMC3682647, DOI: 10.1097/mlr.0b013e3182064aa2.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesClinical trialsPRO instrumentsDisease-specific patient-reported outcomesDisease-specific PRO instrumentsMore PROsUse of PROsPrimary trial outcomeCurrent clinical trialsStudy inclusion criteriaUse of patientMultivariable analysisLarge trialsMajor therapeutic areasInclusion criteriaPRO measurementRelevant outcomesTrial outcomesLogistic regressionClinical researchStudy outcomesPRO outcomesTrialsTherapeutic areasStatistical significance